Development and evaluation of objective trial performance metrics for multisite clinical studies: Experience from the AlcHep Network

dc.contributor.authorDasarathy, Srinivasan
dc.contributor.authorTu, Wanzhu
dc.contributor.authorBellar, Annette
dc.contributor.authorWelch, Nicole
dc.contributor.authorKettler, Carla
dc.contributor.authorTang, Qing
dc.contributor.authorLiangpunsakul, Suthat
dc.contributor.authorGawrieh, Samer
dc.contributor.authorRadaeva, Svetlana
dc.contributor.authorMitchell, Mack
dc.contributor.authorAlcHepNet
dc.contributor.departmentBiostatistics and Health Data Science, Richard M. Fairbanks School of Public Health
dc.date.accessioned2025-03-25T09:05:19Z
dc.date.available2025-03-25T09:05:19Z
dc.date.issued2024
dc.description.abstractBackground: Recruitment and retention are critical in clinical studies but there are limited objective metrics of trial performance. We tested if development of trial performance metrics will allow for objective evaluation of study quality. Performance metrics were developed using data from the observational cohort (OBS) and randomized clinical trial (RCT) arms of the prospective Alcoholic Hepatitis Network. Methods: Yield-rate (%YR; eligible/screened), recruitment index (RI; mean recruitment time/patient), completion index (CI; average number of days to complete the follow-up/patient), and protocol adherence index (AI; average number of deviations/subject recruited) were determined. Results: 2250 patients (1168 for OBS; 1082 for RCT) were screened across 8 sites. Recruitment in the RCT (57% target) was similar to that in the OBS (59% target). Of those screened, 743 (63.6%) subjects in the OBS and 147 (13.6%) subjects in the RCT were enrolled in the study. In OBS study, 253 (34.1%) subjects, and in the RCT, 68 (46.3%) subjects, completed the study or reached a censoring event. Across all sites (range), YR for OBS was 63.6% (41.3-98.3%) and for RCT was 13.6% (5.5-92.6%); RI for OBS was 1.66 (8.79-19.85) and for RCT was 4.05 (19.76-36.43); CI for OBS was 4.87 (22.6-118.3) and for RCT was 8.75 (27.27-161.5); and AR for OBS was 0.56 (0.08-1.04) and for RCT was 1.55 (0.39-3.21. Factors related to participants, research design, study team, and research sponsors contributed to lower performance metrics. Conclusions: Objective measures of clinical trial performance allow for strategies to enhance study quality and development of site-specific improvement plans.
dc.eprint.versionAuthor's manuscript
dc.identifier.citationDasarathy S, Tu W, Bellar A, et al. Development and evaluation of objective trial performance metrics for multisite clinical studies: Experience from the AlcHep Network. Contemp Clin Trials. 2024;138:107437. doi:10.1016/j.cct.2024.107437
dc.identifier.urihttps://hdl.handle.net/1805/46548
dc.language.isoen_US
dc.publisherElsevier
dc.relation.isversionof10.1016/j.cct.2024.107437
dc.relation.journalContemporary Clinical Trials
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectAlcohol-associated hepatitis
dc.subjectClinical trial
dc.subjectPatient screening
dc.subjectRecruitment
dc.subjectRetention of study subjects
dc.titleDevelopment and evaluation of objective trial performance metrics for multisite clinical studies: Experience from the AlcHep Network
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Dasarathy2024Developmen-AAM.pdf
Size:
714.28 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: